HomeServicesMillipore® Contract Testing, Development, and Manufacturing Organization (CTDMO) ServicesViral Vector Contract Testing, Development, & Manufacturing Services (CTDMO)

Viral Vector Contract Testing, Development, & Manufacturing Services (CTDMO)

Viral Vector manufacturing and testing

Advancing Cell and Gene Therapies for Patients

Millipore® CTDMO Services delivers expertise and flexible solutions for viral vector development and manufacturing to advance cell and gene therapies from preclinical through commercial production.

Our proficiency with adeno-associated virus (AAV), lentivirus, adenovirus, and other vectors helps streamline the development and manufacturing of cell and gene therapies. From early preclinical through clinical and commercial manufacturing, we offer the comprehensive resources, capabilities, and know-how to advance current and future cell and gene therapies to market.

Our track record includes successful regulatory inspections by the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, the Australian Therapeutic Goods Administration (TGA), and the Brazilian Health Regulatory Agency (ANVISA).

Talk to an Expert


Gene therapy commercializations supported since 2017


Successful inspections by 6 global regulatory agencies


GMP viral vector batches produced for 200+ clients


Years of viral vector development and manufacturing

Identify and evaluate process improvements to accelerate production timelines

Manufacturability Assessment

Our viral vector experts work with our clients to identify and evaluate improvements to current processes in order to streamline therapeutic production, address risk, and accelerate cell and gene therapies to the clinic. Through our Manufacturability Assessment, we:

  • Incorporate platform technologies for streamlined, scalable production
  • Review critical process parameters (CPPs) and critical quality attributes (CQAs)
  • Recommend adjustments in process design and testing requirements
  • Address other potential risks such as or raw material constraints

Global FootPrint

A Global Footprint

We are a single organization with a global network to deliver CDMO services across all stages of the molecule value chain. Our recently expanded viral vector CDMO campus in Carlsbad, California, USA increases production capacity and allows us to provide end-to-end solutions for viral cell and gene therapies in a single facility.

Carlsbad, CA
Carlsbad, CA

Offering end-to-end viral vector services, our 157,000 sq. ft. state-of-the-art facilities house upstream and downstream production suites, along with fill/finish, warehousing, QC labs, in addition to process and analytical labs to support early phase development to commercial manufacturing of suspension and adherent-based cell and gene therapy platforms.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?